ATHENA: A Phase 3, Open-Label Study Of The Safety And Effectiveness Of Oliceridine (TRV130), A G-Protein Selective Agonist At The µ-Opioid Receptor, In Patients With Moderate To Severe Acute Pain Requiring Parenteral Opioid Therapy

BACKGROUND: Pain management with conventional opioids can be challenging due to dose-limiting adverse events (AEs), some of which may be related to the simultaneous activation of β-arrestin (a signaling pathway associated with opioid-related AEs) and G-protein pathways. The investigational analgesic...

Descripción completa

Detalles Bibliográficos
Autores principales: Bergese, Sergio D, Brzezinski, Marek, Hammer, Gregory B, Beard, Timothy L, Pan, Peter H, Mace, Sharon E, Berkowitz, Richard D, Cochrane, Kristina, Wase, Linda, Minkowitz, Harold S, Habib, Ashraf S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2019
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6861532/
https://www.ncbi.nlm.nih.gov/pubmed/31814753
http://dx.doi.org/10.2147/JPR.S217563

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6861532/
https://www.ncbi.nlm.nih.gov/pubmed/31814753
http://dx.doi.org/10.2147/JPR.S217563

Ejemplares similares